InterCure (INCR.TA) Aktie Kurs

InterCure Ltd is primarily active in the medical cannabis industry.

The main competitors of InterCure Ltd in the market include established companies such as GW Pharmaceuticals, Tilray Inc., and Canopy Growth Corporation. These companies also operate within the medical cannabis industry and compete with InterCure in terms of product development, market share, and innovation. InterCure aims to differentiate itself by offering unique medical cannabis products and focusing on research and development to provide enhanced solutions for patients. Despite facing competition from various industry players, InterCure Ltd continues to strive for growth and maintain its market position through strategic partnerships and constant advancements in the field.

InterCure Ltd, a leading Israeli medical cannabis company, was founded in 2011. With a focus on improving patients' quality of life, InterCure is dedicated to research, development, production, and distribution of medical cannabis products. The company operates under the brand name "Canndoc" and holds a distinctive presence in both domestic and international markets. With a commitment to excellence, InterCure continuously strives to enhance patient care through its state-of-the-art cultivation facilities, advanced research initiatives, and partnerships with renowned international experts. With a rich history of innovation and a commitment to improving global healthcare, InterCure Ltd has established itself as a prominent player in the medical cannabis industry.

InterCure Ltd has achieved several significant milestones since its establishment. The company successfully developed and launched the innovative RESPeRATE device, a non-drug, FDA-cleared solution for hypertension. Additionally, InterCure Ltd has expanded its global presence, establishing partnerships and distribution channels in various markets. The company continues to enhance its product portfolio, offering advanced technologies and solutions to address various medical conditions. InterCure Ltd has also experienced notable financial growth and recognition, attracting investments and receiving prestigious awards for its advancements in healthcare. Overall, the company's milestones highlight its commitment to revolutionizing medical treatments and improving patients' well-being.

InterCure Ltd is primarily present in Israel, the United States, Canada, and Germany.

InterCure Ltd represents a strong commitment to promoting wellness and improving quality of life. The company values include innovation, integrity, and excellence. InterCure focuses on developing and commercializing therapeutic solutions that address unmet medical needs, particularly in the fields of respiratory disease and wellness. The corporate philosophy of InterCure revolves around advancing healthcare through cutting-edge technologies and research. With a dedicated team, InterCure aims to revolutionize the way illnesses are managed and to provide accessible treatments for better health outcomes. interCure Ltd is driven by its mission to enhance well-being and empower individuals to live healthier, more fulfilling lives.

Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 7,14 ILS for InterCure-aktien (median: 7,14 ILS), svarende til -44,2 % i forhold til seneste kurs. Konsensus bygger på 7 analytikervurderinger.

InterCure Analytikerens Kursmål 2026

7 analytikere vurderer i øjeblikket InterCure-aktien: 6 anbefaler køb, 1 hold og 0 salg. For 2026 forventer analytikere, at InterCure genererer omsætning på 574,00 Mio. ILS og indtjening pr. aktie på 1,70 ILS.

InterCure Analytikerens Kursmål 2026

Omregnet til den aktuelle valutakurs handles InterCure-aktien til 3,36 EUR (11,93 ILS).

InterCure-aktien (INCR.TA) er noteret på 2 børser, herunder: NASDAQ (INCR).

InterCure Ltd was founded in 2000 to offer innovative digital health solutions. The company is based in Israel and provides various products and services targeting telemedicine, chronic diseases, and lifestyle management. Telemedicine InterCure offers an award-winning telemedicine platform called "CardioCare". This platform allows doctors to diagnose, treat, and monitor patients with high blood pressure without them having to come to a clinic. The platform includes a wireless blood pressure monitor connected to the patient's "CardioCare" app. By using this technology, the doctor can monitor the patient's blood pressure in real time and adjust the medication accordingly. Chronic diseases InterCure also offers products for managing chronic diseases such as asthma, diabetes, and COPD. The "RespeRate" is a breathing training device designed for patients with respiratory diseases. The device helps regulate breathing rhythm and patterns to improve the quality of breath and reduce symptoms. Lifestyle management Another product offered by InterCure is "Relaxing Moments". This app includes audio and video content for stress management and relaxation. The app was developed in collaboration with leading relaxation and stress reduction experts and includes exercises for breathing, meditation, and mindfulness. InterCure has also partnered with the company "Glucovation" to develop a "Smart Patch" for diabetics. This patch continuously measures blood glucose levels and sends this data to an app on the patient's smartphone. Through these continuous measurements, the patient can adjust medication in real time. Overall, InterCure offers a wide range of products and services aimed at improving patients' health and well-being. By utilizing digital technology, telemedicine, and collaborating with experts in various fields, InterCure supports patients in managing chronic diseases, relaxation, and disease prevention.

forventet-omsætningen for InterCure er 574,00 Mio. ILS. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

forventet-overskuddet for InterCure er 78,13 Mio. ILS. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for InterCure er i øjeblikket 7,00. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af InterCure-aktien.

Pris-til-salgs-forholdet (P/S) for InterCure er i øjeblikket 0,95. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for InterCure-aktien.

AlleAktien-kvalitetsscore for InterCure er 2/10.

ISIN for InterCure er IL0011063760. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for InterCure er A1CZA8. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for InterCure er INCR.TA. Tickersymbolet bruges til at handle InterCure-aktier på børsen.